Drug Trial Radar · NCT00003814
Eflornithine in Treating Patients With Bladder Cancer
Last checked: Nov 20, 2026Latest source record: Dec 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
450
Planned (sponsor's estimate)
Start
Feb 1999
Primary completion
Not stated
Study completion May 2007
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Feb 20, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if eflornithine is more effective than no further therapy in treating bladder cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of eflornithine in treating patients who have newly diagnosed or recurrent bladder cancer.
Conditions
- Bladder Cancer
Interventions
eflornithineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
61 sites in 1 country. Site status is shown where the registry gives one.
Urology Associates
Birmingham, Alabama
Intouch Research
Huntsville, Alabama
Advanced Urology Medical Center
Anaheim, California
Citrus Valley Urological Medical Group
Glendora, California
University of California San Diego Cancer Center
La Jolla, California
San Diego Urology Center
La Mesa, California
South Coast Urological Medical Group
Laguna Hills, California
Foothill Urology Associates
Pasadena, California
San Bernadino Urological Associates
San Bernadino, California
DRC and Urological Physicians of San Diego
San Diego, California
UCSF Cancer Center and Cancer Research Institute
San Francisco, California
Urology Specialists, P.C.
Waterbury, Connecticut
George Washington University Hospital
Washington D.C., District of Columbia
Tampa Bay Meical Research
Clearwater, Florida
University of Florida - Gainesville
Gainesville, Florida
Urology Health Center
New Port Richey, Florida
Barzell, Whitmore, Treiman and Dunne - The Urology Treatment Center
Sarasota, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Piedmont Urology PC
Atlanta, Georgia
Georgia Urology
Atlanta, Georgia
Urology Associates, Inc.
Marietta, Georgia
University of Chicago Cancer Research Center
Chicago, Illinois
Indiana University Cancer Center
Indianapolis, Indiana
University of Kansas Medical Center
Kansas City, Kansas
Wichita Clinic, P.A.
Wichita, Kansas
206 Research Associates
Greenbelt, Maryland
Mid Atlantic Clinical Research
Rockville, Maryland
Lahey Clinic - Burlington
Burlington, Massachusetts
Fallon Clinic, Inc.
Worcester, Massachusetts
Urology Surgical Associates
Springfield, Missouri
Washington University Barnard Cancer Center
St Louis, Missouri
Office of Sheldon Freedman
Las Vegas, Nevada
Robert Wood Johnson Medical School
New Brunswick, New Jersey
University Hospital of New Mexico
Albuquerque, New Mexico
St. Joseph West Mesa Center
Albuquerque, New Mexico
Cancer Center of Albany Medical Center
Albany, New York
Veterans Affairs Medical Center - Albany
Albany, New York
Medical & Clinical Research Associates, LLC
Bay Shore, New York
Mount Sinai Medical Center, NY
New York, New York
University of Rochester Cancer Center
Rochester, New York
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.